Inhibition of hepatitis C virus-transfected cholangiocarcinoma by antisense oligodeoxynucleotide in nude mice

Hepatobiliary and Pancreatic Diseases International

Volumn 3, Issue 1, 2004, Pages 115-119

  Liu, Xiao Fang ^a   Zhou, Xian Ting ^a   Zou, Sheng Quan ^b  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b Tongji Hospital   (China)

Author keywords

Antisense oligodeoxynucleotide; Cholangiocarcinoma; Core gene; HCVmRNA; Hepatitis C virus; Nude mice

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CORE PROTEIN; VIRUS MESSENGER RNA; VIRUS VECTOR;

ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; CARCINOGENICITY; CONTROLLED STUDY; GENETIC TRANSFECTION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INCUBATION TIME; MALE; MOLECULAR CLONING; NONHUMAN; NUDE MOUSE; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INHIBITION; VIRUS RECOMBINANT;

ANIMALS; BASE SEQUENCE; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DISEASE MODELS, ANIMAL; HEPACIVIRUS; MALE; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES, ANTISENSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; VIRAL CORE PROTEINS;

EID: 1342308455     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Chen YD, Liu MY, Yu WL, Li JQ, Peng M, Dai Q, et al. Hepatitis C virus infections and genotypes in China. Hepatobiliary Pancreat Dis Int 2002;1:194-201.
2. Kimura Y, Leung PS, Kenny TP, van de Water J, Nishioka M, Giraud AS, et al, Differential expression of intestinal trefoil factor in biliary epithelial cells of primary biliary cirrhosis. Hepatology 2002;36:1227-1235.
3. Liu XF, Zou SQ, Qiu FZ. Construction of HCV-core gene vector and its expression in cholangiocarcinoma. World J Gastroenterol 2002;8:135-138.
4. Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 2002;17:1049-1055.
5. Mizutani T, Kato N, Hirota M, Sugiyama K, Murakami A, Shimotohno K. Inhibition of hepatitis C virus replication by antisense oligonucleotide in culture cells. Biochem Biophys Res Commun 1995;212:906-911.
6. Wakita T, Wands JR. Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotide. In vitro model for selection of target sequence. J Biol Chem 1994;269:14205-14210.
7. Fukuma T, Walton CM, Wu CH, Wu GY. Conjugation of an antisense oligodeoxynucleotide to ribonuclease h results in sequence-specific cleavage and intracellular inhibition of HCV gene expression. Bioconjug Chem 2003;14:295-301.
8. Ideo G, Bellobuono A. New therapies for the treatment of chronic hepatitis C. Curr Pharm Des 2002;8:959-966.
9. Caselmam WH, Eisehardt S, Alt M. Synthetic antisense oligodeoxynucleotides as potential drugs against hepatitis C. Intervirology 1997;40:394-399.
10. Alt M, Renz R, Hofschneider PH, Paumgartner G, Caselmann WH. Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology 1995;22:707-717.
11. Alt M, Renz R, Hofschneider PH, Caselmann WH. Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation. Arch Virol 1997;142:589-599.
12. Ray RB, Lagging LM, Meyer K, Ray R. Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res 1995;37:209-220.
13. Tsuchihara K, Hijikata M, Fukuda K, Kuroki T, Yamamoto N, Shimotohno K. Hepatitis C virus core protein regulates cell growth and signal transduction pathway transmitting growth stimuli. Virology 1999;258:100-107.
14. Yao ZQ, Ray S, Eisen-Vandervelde A, Waggoner S, Hahn YS. Hepatitis C virus: immunosuppression by complement regulatory pathway. Viral Immunol 2001;14:277-295.
15. Basu A, Meyer K, Ray RB, Ray R. Hepatitis C virus core protein is necessary for the maintenance of immortalized human hepatocytes. Virology 2002;298:53-62.
16. Watashi K, Shimotohno K. The roles of hepatitis C virus proteins in modulation of cellular functions: a novel action mechanism of the HCV core protein on gene regulation by nuclear hormone receptors. Cancer Sci 2003;94:937-943.
17. Ishikawa T, Shibuga K, Vasui K, Mitamura K, Veda S. Expression of hepatitis C virus core protein associated with malignant lymphoma in transgenic mice. Comp Immunol Microbiol Infeet Dis 2003;26:115-124.
18. Ray RB, Steele R, Meyer K, Ray R. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 1997;272:10983-10986.
19. Reeves ME, Dematteo RP. Genes and viruses in hepatobiliary neoplasia. Semin Surg Oncol 2000;19:84-93.
20. Moradpour D, Englert C, Wakita T, Wends JR. Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology 1996;222:51-63.
21. Zhang H. Lethality in mice infected with recombinant vaccinia virus expressing hepatitis C virus core protein. Hepatobiliary pancreat Dis Int 2003;2:374-382.
22. Ray RB, Meyer K, Ray R. Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 1996;226: 176-182.
23. Marusawa H, Hijikata M, Chiba T, Shimotohno K. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-κB activation. J Virol 1999;73: 4713-4720.
24. Ray RB, Meyer K, Ray R. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology 2000;271:197-204.
25. Ray RB, Ray R. Hepatitis C virus core protein: intriguing properties and functional relevance. Micrbiol Lett 2001;202: 149-156.
26. Hahn CS, Cho YG, Kang BS, Lester IM, Hahn YS. The HCV core protein acts as a positive regulator of fas-mediated apoptosis in a human lymphoblastoid T cell line. Virology 2000;276:127-137.
27. Sacco R, Tsutsumi T, Suzuki R, Otsuka M, Aizaki H, Sakamoto S, et al. Antiapoptotic regulation by hepatitis C virus core protein through up-regulation of inhibitor of capase-activated DNase. Virology 2003;17:24-35.
28. Kountouras J, Zavos C, Chatzopoulos D. Apoptosis in hepatitis C. J Viral Hepat 2003;10:335-342.
29. Ruggieri A, Murdolo M, Rapicetta M. Induction of Fas ligand expression in a human hepatoblastoma cell line by HCV core protein. Virus Res 2003;97:103-110.
30. Moldvay J, Deny D, Pol S, Brechot C, Lamas E. Detection of hepatitis C virus RNA in peripheral blood mononuclear cells of infected patients by in situ hybridization. Blood 1994;38: 269.
31. Shimizu YK, Iwamoto A, Hijikata M, Purcell RH, Yoshikura H. Evidence of in vitro replication of hepatitis C virus genome in a human T-cell line. Proc Natl Acad Sci USA 1993;89: 5477-5481.
32. Kato N, Nakazawa T, Mizutani T, Shimotohno K. Susceptibility of human T-lymphotropic virus type I infected cell line MT-2 to hepatitis C virus infection. Biochem Bio Res Commun 1995;26:863-869.
33. Dominguez MH, Gaytan GS. Hepatocellular carcinoma: an update. Ultrastruct Pathol 2001;25:497-516.
34. Zhao W, Wan JM, Liu W, Liu QJ, Zhang L, Zhou ZX, et al. Hepatitis gene chip in detecting HBV DNA, HCV RNA in serum and liver tissue samples of hepatitis patients. Hepatobiliary Pancreat Dis Int 2003;2:234-241.
35. Goldin RD, Patel NK, Thomas HE. Hepatitis C and bile duct loss. J Clin Pathol 1996;49:836.
36. Rozario R, Ramakrishna B. Histopathological study of chronic hepatitis B and C: a comparison of two scoring systems. J Hepatol 2003;38:223-229.
37. Uenishi T, Kubo S, Hirohashi K, Yamamoto T, Kinoshita H. Expression of bile duct-type cytokeratin in hepatocellular carcinoma. in patients with hepatitis C virus and prior hepatitis B virus infection. Cancer Lett 2002;178:107-112.
38. Chu C, Hwang S, Luo J, Wang Y, Lu R, Lai C, et al. Clinical, virological, immunological, and pathological significance of GB virus C/hepatitis G infection in patients with chronic hepatitis C. Hepatol Res 2001;19:225-236.
39. Herrmann G. Immunohistochemical study of HBV antigen in 338 liver cell carcinomas. Z Gastroenterol 1999;37:329-342.
40. Lu H, Ye MQ, Thung SN, Dash S, Gerber MA. Detection of hepatitis C virus RNA sequences in cholangiocarcinomas in Chinese and American patients. Chin Med J 2000;113:1138-1141.
41. Kobayashi M, Ikeda K, Saitoh S, Suzuki F, Tsubota A, Suzuki Y, et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer 2000;88:2471-2477.
42. Yamamoto M, Takasaki K, Nakano M, Saito A. Minute nodular intrahepatic cholangiocarcinoma. Cancer 1998;82:2145-2149.
43. Guo ZJ, Li Q, He K. Diagnosis and treatment of hepatic cholangiocarcinoma: report of 52 cases. Hepatobiliary Pancreat Dis Int 2003;2:62-65.
44. Suriawinata A, Ivanov K, BenHaim M, Schwartz ME. A 67-year-old man with hepatitis C virus infection and a liver tumor. Semin Liver Dis 2000;20:227-231.
45. Liu XF, Zou SQ, Qiu FZ. Pathogenesis of cholangiocarcinoma in the porta hepatis and infection of hepatitis virus. Hepatobiliary Pancreat Dis Int 2003;2:285-289.